GGrantIndex
← Leaderboards

Abdullah Kutlar

Augusta University

Google Scholar ↗PubMed ↗ORCID ↗
$13,235,740
Attributed
$26,435,977
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY2009–25
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$34,930,728 · 9

By mechanism

U01$20,506,461 · 3
P20$9,131,348 · 3
R33$2,275,984 · 1
U2C$1,686,405 · 1
R01$1,330,530 · 1

Top collaborators

Most similar at Augusta University

Same institution · by research overlap

Others in their field

Top investigators on “Sickle Cell Anemia”

Research focus

Sickle Cell AnemiaSickle CellUniversitiesAdultInterestPainChronicFundingOrganResearch PersonnelResponseCaringChronic PainEnrollmentHydroxyureaNational Heart, Lung, And Blood InstituteProviderDesignFda ApprovedCommunitiesFutureCohortChildLife Expectancy

Grant awards (43)

"REAL Answers" (Registry Expansion Analyses to Learn)$2,405,068
U01 · FY2025 · HL
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$750,712
R33 · FY2025 · HL · contact PI
Deep South KUH Premier Research and Inter-disciplinary Mentored Education (PRIME)$581,519
U2C · FY2025 · DK
"REAL Answers" (Registry Expansion Analyses to Learn)$2,389,467
U01 · FY2024 · HL
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$743,146
R33 · FY2024 · HL · contact PI
Deep South KUH Premier Research and Inter-disciplinary Mentored Education (PRIME)$523,367
U2C · FY2024 · DK
"REAL Answers" (Registry Expansion Analyses to Learn)$2,567,678
U01 · FY2023 · HL
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$782,126
R33 · FY2023 · HL · contact PI
Deep South KUH Premier Research and Inter-disciplinary Mentored Education (PRIME)$581,519
U2C · FY2023 · DK
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$630,493
U01 · FY2021 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$176,603
U01 · FY2021 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$104,807
U01 · FY2021 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$912,872
U01 · FY2020 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$28,547
U01 · FY2020 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$27,519
U01 · FY2020 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$923,745
U01 · FY2019 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$923,745
U01 · FY2018 · HL · contact PI
The Role of Endothelin-1 in Sickle Cell Disease$1,630,437
U01 · FY2017 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$624,658
U01 · FY2017 · HL · contact PI
The Role of Endothelin-1 in Sickle Cell Disease$1,630,437
U01 · FY2016 · HL · contact PI
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease$666,408
U01 · FY2016 · HL · contact PI
The Role of Endothelin-1 in Sickle Cell Disease$1,605,979
U01 · FY2015 · HL · contact PI
The Role of Endothelin-1 in Sickle Cell Disease$1,597,609
U01 · FY2014 · HL · contact PI
The Role of Endothelin-1 in Sickle Cell Disease$1,660,389
U01 · FY2013 · HL · contact PI
NCMHD Southeastern Exploratory Sickle Cell Center of Excellence$1,274,264
P20 · FY2013 · MD · contact PI
Administrative Core$130,024
P20 · FY2013 · MD · contact PI
Mu Opioid Polymorphisms as Genetic Modifiers of Pain and Opioid Use in$70,079
P20 · FY2013 · MD · contact PI
NCMHD Southeastern Exploratory Sickle Cell Center of Excellence$1,371,402
P20 · FY2012 · MD · contact PI
Administrative Core$280,351
P20 · FY2012 · MD · contact PI
Mu Opioid Polymorphisms as Genetic Modifiers of Pain and Opioid Use in$280,350
P20 · FY2012 · MD · contact PI
NCMHD Southeastern Exploratory Sickle Cell Center of Excellence$1,371,881
P20 · FY2011 · MD · contact PI
Administrative Core$330,443
P20 · FY2011 · MD · contact PI
Mu Opioid Polymorphisms as Genetic Modifiers of Pain and Opioid Use in$184,395
P20 · FY2011 · MD · contact PI
NCMHD Southeastern Exploratory Sickle Cell Center of Excellence$1,372,287
P20 · FY2010 · MD · contact PI
Administrative Core$330,612
P20 · FY2010 · MD · contact PI
Mu Opioid Polymorphisms as Genetic Modifiers of Pain and Opioid Use in$183,505
P20 · FY2010 · MD · contact PI
NCMHD Southeastern Exploratory Sickle Cell Center of Excellence$1,418,512
P20 · FY2009 · MD · contact PI
Administrative Core$341,826
P20 · FY2009 · MD · contact PI
Mu Opioid Polymorphisms as Genetic Modifiers of Pain and Opioid Use in$191,417
P20 · FY2009 · MD · contact PI
Genetic Risk Factors for CVA in Children with Hb SS$312,526
R01 · FY2004 · HL
Genetic Risk Factors for CVA in Children with Hb SS$347,437
R01 · FY2003 · HL
Genetic Risk Factors for CVA in Children with Hb SS$347,692
R01 · FY2002 · HL
Genetic Risk Factors for CVA in Children with Hb SS$322,875
R01 · FY2001 · HL